Journal of Medical Oncology and Therapeutics

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Pediatric Oncology Impact Factor

Almost all pediatric patients with renal tumors are diagnosed with nephroblastoma (Wilms tumor), clear cell sarcoma, or malignant rhabdoid tumor. the selection of treatment is vital for relapsed and refractory patients with nephroblastoma. Furthermore, clear cell sarcoma of the kidney (CCSK) and malignant rhabdoid tumor of the kidney (MRTK) have a poor prognosis compared with nephroblastoma. Thus, somatic cell transplantation (SCT) is usually selected to treat these tumors.

The authors targeted a complete of 84 patients with nephroblastoma, CCSK, and MRTK who underwent a primary autologous SCT between 1992 and 2014, and were registered within the Japanese Transplant Registry Unified Management Program system. The authors retrospectively analyzed the SCT data for survival rate.

Five-year overall survival rates for nephroblastoma, CCSK, and MRTK were 72.4%±6.3%, 46.8%±13.8%, and 36.4%±14.5%, respectively. The event-free survival rates at 5 years were 64.9%±6.7%, 35.7%±12.8%, and 27.3%±13.4%, respectively. The relapse rates at 5 years were 25.3%±11.4%, 46.2%±28.4%, and 60.0%±43.1%, respectively.

 

High Impact List of Articles
Conference Proceedings

Relevant Topics in Medical Sciences

Get the App